期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 13, 期 12, 页码 1555-1568出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.13.12.1555
关键词
antiangiogenesis; chemotherapy; endocrine therapy; HCC; systemic therapy; signal transduction inhibition
For the minority of patients with hepatocellular carcinoma (HCC), surgical or locally ablative therapies may offer the prospect of cure. However, the majority of patients present with advanced disease such that treatment with curative intent is no longer possible. For some of these patients, with good hepatic reserve and a patent portal venous system, chemoembolisation may afford a modest survival benefit. The remainder of patients are frequently treated with systemic therapies with palliative intent. This review aims to summarise the current systemic treatment approaches for HCC in the adjuvant and palliative setting before reviewing the evidence for novel therapies emerging in this field. At present there are a number of interesting therapeutic agents with potential activity in HCC. The challenge now is the design of clinical trials to optimally evaluate these agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据